Table 1.
Comparison of general information
| Control group (n = 53) | Experimental group (n = 61) | t/χ2 | P value | |
| Gender (cases) | 0.216 | 0.642 | ||
| Male | 38 (71.70) | 42 (68.85) | ||
| Female | 15 (28.30) | 19 (31.15) | ||
| Age (yr) | 52.64 ± 12.85 | 53.14 ± 12.93 | 0.207 | 0.837 |
| BMI (kg/m2) | 26.84 ± 3.42 | 26.94 ± 3.36 | 0.157 | 0.875 |
| Course of disease (yr) | 2.56 ± 0.58 | 2.67 ± 0.59 | 1.001 | 0.319 |
| Time for intensive care unit treatment before enrollment (d) | 2.13 ± 1.03 | 2.16 ± 1.05 | 0.154 | 0.878 |
| Pathogenic bacteria (cases) | 1.092 | 0.579 | ||
| Gram-negative bacteria | 31 (58.49) | 34 (55.74) | ||
| Gram-positive bacteria | 19 (35.85) | 21 (34.43) | ||
| Mixed infection | 3 (5.66) | 6 (9.84) | ||
| Causes (cases) | 0.147 | 0.986 | ||
| Severe pancreatitis | 14 (26.42) | 16 (26.23) | ||
| Pneumonia | 21 (39.62) | 25 (40.98) | ||
| Non-suppurative cholangitis | 12 (22.64) | 13 (21.31) | ||
| Unknown causes | 6 (11.32) | 7 (11.48) | ||
| SOFA score (points) | 10.38 ± 1.03 | 10.36 ± 1.06 | 0.102 | 0.919 |
| APACHE II score (points) | 23.91 ± 2.17 | 23.67 ± 2.11 | 0.598 | 0.551 |
| RIFLE classification (cases) | 0.040 | 0.980 | ||
| Risk period | 11 (20.75) | 12 (19.67) | ||
| Injury period | 17 (32.08) | 20 (32.79) | ||
| Failure period | 25 (47.17) | 29 (47.54) | ||
| Diabetes (cases) | 0.185 | 0.667 | ||
| Yes | 21 (39.62) | 26 (42.62) | ||
| No | 32 (60.38) | 35 (57.38) | ||
| Hypertension (cases) | 0.020 | 0.887 | ||
| Yes | 23 (43.40) | 27 (44.26) | ||
| No | 30 (56.60) | 34 (55.74) |
SOFA score: Sequential Organ Failure Assessment score; APACHE II score: Acute Physiology, Age, and Chronic Health Evaluation score; RIFLE classification: Risk, Injury, Failure, Loss, and End-stage renal failure; BMI: Body mass index.